Updates in Characteristics and Survival Rates of Hepatocellular Carcinoma in a Nationwide Cohort of Real-World US Patients, 2003–2021

References

• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650–2666. doi:10.1016/j.cgh.2019.07.060
   PubMed Web of Science ®Google Scholar
• Kim NG, Nguyen PP, Dang H, et al. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015. Cancer. 2018;124(12):2588–2598. doi:10.1002/cncr.31373
   PubMed Web of Science ®Google Scholar
• Younossi Z, Stepanova M, Ong JP, et al. Global nonalcoholic steatohepatitis council: nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–755.e3. doi:10.1016/j.cgh.2018.05.057
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–1730. doi:10.1002/hep.28123
   PubMed Web of Science ®Google Scholar
• Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28.9. doi:10.1016/j.cgh.2021.12.002
   PubMed Web of Science ®Google Scholar
• Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752.
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Mathur K, Mazhar A, Patel M, et al. Changing trends of cirrhotic and noncirrhotic hepatocellular carcinoma in the era of directly-acting antiviral agents. Clin Transl Gastroenterol. 2021;12(11):e00420. doi:10.14309/ctg.0000000000000420
   PubMed Web of Science ®Google Scholar
• Paik JM, Younossi Y, Henry L, Mishra A, Younossi ZM. Recent trends in the global burden of hepatitis B virus: 2007–2017. Gastroenterology. 2021;160(5):1845–1846.e3. doi:10.1053/j.gastro.2020.11.057
   PubMed Web of Science ®Google Scholar
• Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019;3(11):1459–1471. doi:10.1002/hep4.1419
   PubMed Web of Science ®Google Scholar
• Stanford Center for Population Health Sciences. Optum DOD (v 5.0). Redivis Dataset; 2021. Available from: https://redivis.com/StanfordPHS. Accessed 31 August 2022.
   Google Scholar
• Fernandes G, Campos D, Ballalai A, et al. Epidemiological and clinical patterns of newly diagnosed hepatocellular carcinoma in Brazil: the need for liver disease screening programs based on real-world data. J Gastrointest Cancer. 2021;52(3):952–958. doi:10.1007/s12029-020-00508-7
   PubMed Web of Science ®Google Scholar
• Yeo YH, Hwang J, Jeong D, et al. Surveillance of patients with cirrhosis remains suboptimal in the United States. J Hepatol. 2021;75(4):856–864. doi:10.1016/j.jhep.2021.04.042
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027. doi:10.1177/2049936120965027
   Web of Science ®Google Scholar
• Huang DQ, Hoang JK, Nguyen MH. HBV-related hepatocellular carcinoma: a call to improve surveillance and linkage to care. Liver Int. 2021;41(9):2238–2239. doi:10.1111/liv.15023
   PubMed Web of Science ®Google Scholar
• Kim NJ, Locke CJ, Park H, Magee C, Bacchetti P, Khalili M. Race and hepatitis C care continuum in an underserved birth cohort. J Gen Intern Med. 2019;34(10):2005–2013. doi:10.1007/s11606-018-4649-6
   PubMed Web of Science ®Google Scholar
• Moon AM, Curtis B, Mandrekar P, Singal AK, Verna EC, Fix OK. Alcohol-associated liver disease before and after COVID-19: an overview and call for ongoing investigation. Hepatol Commun. 2021;5(9):1616–1621. doi:10.1002/hep4.1747
   PubMed Web of Science ®Google Scholar
• Jun TW, Yeh ML, Yang JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018;38(5):895–902. doi:10.1111/liv.13613
   PubMed Web of Science ®Google Scholar
• Younossi Z, Stepanova M, Sanyal AJ, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol. 2018;69(6):1365–1370. doi:10.1016/j.jhep.2018.08.013
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8(4):346–352. doi:10.1016/S1665-2681(19)31748-X
   PubMed Web of Science ®Google Scholar
• Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med. 2020;287(6):711–722. doi:10.1111/joim.13035
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5(11):1833–1847. doi:10.1002/hep4.1765
   PubMed Web of Science ®Google Scholar
• Rai B, Albertian R, Solano L, et al. Lack of liver disease awareness: important contributor to late state hepatocellular carcinoma. Hepatology. 2020;72(S1)644A.
   Google Scholar
• Younossi ZM, Ong JP, Takahashi H, et al. Global nonalcoholic steatohepatitis council: a global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(6):e1456–e1468. doi:10.1016/j.cgh.2021.06.048
   PubMed Web of Science ®Google Scholar
• Turse E, Aboona M, Charley E, et al. Factors associated with survival of hepatocellular carcinoma (HCC) patients at a safety net hospital in Arizona without on-site liver transplant program. J Hepatocell Carcinoma. 2022;9:1–11. doi:10.2147/JHC.S341690
   PubMed Web of Science ®Google Scholar
• Estevez J, Yang JD, Leong J, et al. Clinical features associated with survival outcome in African-American patients with hepatocellular carcinoma. Am J Gastroenterol. 2019;114(1):80–88.
   PubMed Web of Science ®Google Scholar